This Stock-Split Stock Is Up 90% in the Past 6 Months: Is There More Upside Ahead?

Tilray Brands enacted a 1-for-10 reverse stock split (approved June 10, implemented Dec. 2) after a recent six‑month 90% rally to lift the post‑split share price to about $7 and avoid Nasdaq delisting. The company reported an unexpected net profit in Q1 fiscal 2026 (quarter ended Aug. 31), but the article highlights persistent inconsistent organic revenue, historical net losses, and a challenging regulatory backdrop — including a federal hemp‑THC ban and only speculative prospects for U.S. legalization — leaving the author bearish on Tilray's prospects and recommending avoiding the stock.

Analysis

Market structure: The reverse 1-for-10 split is a de facto signal of stress — losers are small- and mid-cap cannabis issuers with weak balance sheets (TLRY, CWBHF) while winners are better-capitalized MSOs and Canadian leaders (CGC, CURLF, GTBIF) that can absorb price deflation and pursue consolidation. Oversupply in Canada and state markets keeps wholesale flower prices depressed; pricing power will concentrate with operators that control retail footprint or low-cost production, shifting share to vertically integrated players over 6–24 months. Cross-asset: expect wider credit spreads for cannabis debt (>>100–300bp move vs. IG), elevated equity implied vol and skew, and limited FX/commodity impact beyond hemp feedstock prices falling on regulatory bans.

Key Decisions for Investors

• Establish a tactical short in TLRY equal to 2–3% of portfolio NAV via equity or a 9–12 month put spread (buy 12‑month $5 put, sell $2.50 put) with a target 50–70% downside over 6–12 months and a hard stop at +35% from entry.
• Execute a dollar‑neutral pair: short TLRY (2% NAV) and long Canopy Growth (CGC, 2% NAV) for 6–12 months to capture consolidation/relative quality; exit if relative performance reverses by 20% or after a positive DOJ rescheduling announcement within 12 months.
• Reduce total cannabis sector exposure to <1% of equity book within 30 days; redeploy 1–2% into defensive beverage/consumer names with stable cash flow such as Constellation Brands (STZ) or Altria (MO) for a 12‑month hold due to lower regulatory beta.
• Monitor three hard triggers over next 30–360 days and act deterministically: (A) DOJ rescheduling to Schedule III or federal legalization language — cover shorts within 2 weeks and rotate into TLRY/CGC up to 2–3%; (B) new federal hemp‑THC restrictive regs — accelerate shorts and increase puts on exposed tickers; (C) two consecutive quarters of organic revenue growth and positive EBITDA for TLRY — trim/close short position and reassess.